Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center | Zendy

Haobo Huang | Zendy; Liping Fan | Zendy; Danhui Fu | Zendy; Qiuyan Lin | Zendy; Jianzhen Shen | Zendy

Open Access

Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center

Author(s) -

Haobo Huang,

Liping Fan,

Danhui Fu,

Qiuyan Lin,

Jianzhen Shen

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-19-589

Subject(s) - medicine , international prognostic index , rituximab , diffuse large b cell lymphoma , vincristine , chop , regimen , oncology , b symptoms , performance status , univariate analysis , prednisone , single center , lymphoma , cyclophosphamide , chemotherapy , multivariate analysis

The CHOP regimen comprising cyclophosphamide, doxorubicin, vincristine, and prednisone is a basic chemotherapeutic regimen for diffuse large B cell lymphoma (DLBCL). Addition of rituximab (R) to chemotherapy has led to better efficacy than other regimens in clinical trials. However, data of clinical characteristics and outcomes of patients with DLBCL are scarce. Therefore, this study reports the clinical characteristics, treatment, and outcomes of patients with DLBCL in our hospital.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research